Key clinical point : Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.
Major finding : Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.
Study details : The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.
Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.
Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098